Home
About Us
Membership
Member Biography

Member Biography

Nabil Adra, MD

Nabil Adra, M.D.

Phone: (317) 278-7728
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 473
Indianapolis, IN 46202

Faculty appointments

Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate Professor of Clinical Urology, Department of Urology, IU School of Medicine
Rikki and Leonard Goldstein Scholar in Cancer Research
Full member, Experimental and Developmental Therapeutics

Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015IUSCC-0579

Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University IUSCC-0611

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)C16-174

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)EA8143

COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAMIUSCC-0584

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 TrialEA8153

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the Bladder (ADAPT)GU16-243

A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors IUSCC-0688

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate CancerCTO-20180146

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder CancerCTO-MK-3475-B15

PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXELNRG-GU002

MicroRNA testing in patients with testicular cancerIUSCC-0712

Genomic Analysis of Relapsed/Refractory Germ-Cell TumorsIUSCC-0708

Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients with Rising PSA at High-Risk of Progression after Primary TherapyE2809

A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) CTO-MK-3475-905

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)CTO-MK-3475-866

A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORSCTO-S1823

Retrospective Analysis of Patients with Renal Cell Carcinoma at Indiana University: 1990-2021CTO-IUSCCC-0785

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)CTO-CAAA617C12301

A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid TumorsCTO-PT112-101

Circulating Tumor DNA in Early Stage and Metastatic Non-Seminomatous Germ Cell Testicular CancerCTO-IUSCCC-0789

Sequelae of Treatment in Survivors of Testicular Cancer Creation of a Non-exposed Comparison Group for the Platinum Study IUSCC-0587

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell TumorCTO-IUSCCC-0742

A PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH ENTINOSTAT AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMAIUSCC-0574

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination with Androgen Receptor Pathway Inhibitors in Subjects with Metastatic Prostate CancerCTO-ARX517-2011

A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) rosopatamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen Receptor Pathway Inhibitor TreatmentCTO-177LU-TLX591-203

Expression of Nectin-4 in germ-cell tumors IUSCCC-0833

PSMAcTION: A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.CTO-CAAA817A12201

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With ChemotherapyCTO-20230005

A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)CTO-CJSB462B12201

Circulating Tumor DNA in High-Risk Stage I and Clinical Stage II Germ-cell TumorsCTO-IUSCCC-0937

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid TumorsCTO-XMAB541-01

A Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced relapsed or refractory germ cell tumours, endometrial cancer, or ovarian cancerCTO-BIPI-2001-0001

Headlines & highlights

#ResearchCuresCancer

Support Our Research